SCHEMBL22794560

SCHEMBL22794560

O=c1nc2n(c3ccccc13)CC/C2=C\N1CCCCC1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SMARCA4 P51532 8/20 1.00
▸ PBRM1 Q86U86 8/20 1.00
▸ SMARCA2 P51531 2/20 0.55
▸ HPGD P15428 2/20 0.48
▸ HSD17B10 Q99714 2/20 0.48
▸ KDM4E B2RXH2 1/20 0.48
▸ MEN1 O00255 3/20 0.44
▸ KMT2A Q03164 3/20 0.44
▸ MAPT P10636 3/20 0.44
▸ ALDH1A1 P00352 2/20 0.44
▸ MAPK1 P28482 1/20 0.44
▸ HDAC6 Q9UBN7 1/20 0.38
▸ NPC1 O15118 1/20 0.37
▸ CYP1A2 P05177 1/20 0.37
▸ CYP3A4 P08684 1/20 0.37
▸ CYP2D6 P10635 1/20 0.37
▸ CYP2C9 P11712 1/20 0.37
▸ CYP2C19 P33261 1/20 0.37
▸ RAB9A P51151 1/20 0.37
▸ SMN1; SMN2 Q16637 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22794557 0.99 SMARCA4 (1.00) SMARCA4PBRM1SMARCA2HPGDHSD17B10
SCHEMBL22794550 0.88 SMARCA4 (1.00) SMARCA4PBRM1SMARCA2HPGDHSD17B10
SCHEMBL22794544 0.88 SMARCA4 (0.81) SMARCA4PBRM1SMARCA2HPGDHSD17B10
SCHEMBL22794558 0.88 SMARCA4 (1.00) SMARCA4PBRM1SMARCA2HPGDHSD17B10
SCHEMBL22794536 0.85 SMARCA4 (1.00) SMARCA4PBRM1SMARCA2HPGDHSD17B10
SCHEMBL22794539 0.81 PBRM1 (1.00) SMARCA4PBRM1SMARCA2HSD17B10MEN1
SCHEMBL22794541 0.80 SMARCA4 (1.00) SMARCA4PBRM1SMARCA2HPGDHSD17B10
SCHEMBL22794538 0.80 PBRM1 (0.98) SMARCA4PBRM1SMARCA2HSD17B10MEN1
SCHEMBL24743546 0.77 PBRM1 (1.00) SMARCA4PBRM1SMARCA2HPGDHSD17B10
SCHEMBL21992769 0.77 SMARCA4 (0.64) SMARCA4PBRM1SMARCA2HPGDHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230072658-A1 SMARCA DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2023-03-09 — — US disclosed
WO-2022125804-A1 SMARCA DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. (US) 2022-06-16 — — WO disclosed
WO-2020251971-A1 SMARCA DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. (US) 2020-12-17 — — WO disclosed
WO-2020251969-A1 SMARCA DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. (US) 2020-12-17 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230072658-A1 SMARCA DEGRADERS AND USES THEREOF SMARCA1, SMARCB1, SMARCE1 SMARCA4 5/4885PBRM1 11/4885SMARCA2 4/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback